EUVIMEDEUVIMED entdecken
Crossref

Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma

Sho Iwaki, Shigenori Kadowaki, Kazunori Honda, Yukiya Narita, Toshiki Masuishi, Hiroya Taniguchi, Masashi Ando, Kei Muro, Michi Sawabe, Hidenori Suzuki, Daisuke Nishikawa, Shintaro Beppu und 4 weitere

International Journal of Clinical Oncology · 2024-06 · 29 (6) · 764-770

DOI: 10.1007/s10147-024-02508-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 30.03.2024. Verfasst von Sho Iwaki und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pembrolizumab alone or combined with chemotherapy is the standard of care for first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) with positive programmed death-ligand 1 combined positive scores. However, data on second-line chemotherapy following pembrolizumab are scarce. METHODS: A single-center, retrospective study was conducted to determine the efficacies of pembrolizumab and pembrolizumab plus chemotherapy as first-line treatments and the efficacy of second-line chemotherapy for patients with R/M HNSCC who were refractory or intolerant to first-line treatment. RESULTS: Fifty-four patients were treated with pembrolizumab, and 29 received second-line therapy, with 27 opting for cetuximab-containing regimens. The median progression-free survival (PFS), overall survival (OS), and PFS on next-line therapy for first-line treatment were 4.7 (95% confidence interval [CI], 2.1-8.7), 22.1 (95% CI, 12.6-not reached), and 15.6 months (95% CI, 9.7-not reached) in the pembrolizumab group and 5.4 (95% CI, 3.3-6.8), 15.8 (95% CI, 8.6-not reached), and 13.7 months (95% CI, 8.1-not reached) in the pembrolizumab plus chemotherapy group, respectively. The overall response rate and median PFS for second-line treatment were 48.3% (95% CI, 30.4-67.0) and 6.1 months (95% CI, 2.30-8.84). The median OS for patients who received second-line treatment was 18.4 months, which was superior to the median OS of 6.0 months for patients who received the best supportive care (log-rank p = 0.10). CONCLUSION: This study indicates that cetuximab-containing second-line chemotherapy can improve outcomes in R/M HNSCC, even after first-line therapy failure or intolerance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedSquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultProgression-Free SurvivalAged, 80 and over

Stichwörter der Autor:innen

ChemotherapyCombined positive scoreHead and neck squamous cell carcinomaPembrolizumabSurvival

Substanzen

pembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan. skadowaki@aichi-cc.jp.
  • Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Osaka University Graduate School of Medicine, Suita, Japan.

Zitieren

APA

Iwaki, S., Kadowaki, S., Honda, K., Narita, Y., Masuishi, T., Taniguchi, H., Ando, M., Muro, K., Sawabe, M., Suzuki, H., Nishikawa, D., Beppu, S., Terada, H., Kishikawa, T., Kawakita, D., & Hanai, N. (2024). Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma. International Journal of Clinical Oncology, 29(6), 764-770. https://doi.org/10.1007/s10147-024-02508-0

Vancouver

Iwaki S, Kadowaki S, Honda K, Narita Y, Masuishi T, Taniguchi H, et al. Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma. International Journal of Clinical Oncology. 2024;29(6):764-770. doi:10.1007/s10147-024-02508-0

BibTeX
@article{Iwaki2024,
  author = {Iwaki, Sho and Kadowaki, Shigenori and Honda, Kazunori and Narita, Yukiya and Masuishi, Toshiki and Taniguchi, Hiroya and Ando, Masashi and Muro, Kei and Sawabe, Michi and Suzuki, Hidenori and Nishikawa, Daisuke and Beppu, Shintaro and Terada, Hoshino and Kishikawa, Toshihiro and Kawakita, Daisuke and Hanai, Nobuhiro},
  title = {Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  volume = {29},
  number = {6},
  pages = {764--770},
  doi = {10.1007/s10147-024-02508-0}
}
Kostenlos starten →